What happened to Peptide Sciences?
On March 6, 2026, Peptide Sciences, long the highest-traffic research peptide vendor in the United States, closed its doors and stopped taking orders. There was no runway, no notice, and no conversation with the customers or research partners who depended on the company. Where a full catalog once sat, the domain now resolves to a single shutdown notice.
The scale of what disappeared is worth sitting with. In its final stretch, Peptide Sciences was pulling in an estimated $7.4 million per month and drawing roughly 990,000 monthly visits, according to third-party traffic analytics. More than a decade of operation had made it one of the most familiar names in the field, with a shelf of over 190 research compounds covering growth hormone secretagogues, metabolic peptides, tissue repair factors, cognitive research compounds, and longevity-related peptides.
What made the closure sting was the silence around it. No detailed statement explained the decision. Open orders were reportedly canceled, and support channels stopped answering within days. Researchers describe the same experience over and over: no email, no fulfillment timeline, no word on refunds. Within hours, forums and social feeds filled with people working every contact method they could find, trying to reach a company that had already gone quiet.
For the researchers who had leaned on Peptide Sciences as their one supplier, often for years, the disruption was immediate and structural. Grant-funded academic labs running to fixed timelines felt it hardest, because qualifying a replacement vendor and confirming that a new source's compounds match the old one is not a same-week task. It runs weeks, sometimes months.
None of this happened in isolation. The shutdown landed in the middle of the most aggressive regulatory push the peptide sector has seen, which has led a lot of observers to read it the same way: Peptide Sciences appears to have chosen to walk before it was pushed. To understand that read, you have to look at the regulatory and quality picture that built up in the months beforehand.
Why did Peptide Sciences shut down?
No single event closed Peptide Sciences. What ended the company was a stack of pressures that built through 2025 and into early 2026, each one raising the legal and financial cost of staying open until the math stopped working. Here is what accumulated.
FDA enforcement escalation. Starting in September 2025, the FDA sent more than 50 warning letters to peptide vendors, compounding pharmacies, and adjacent businesses. The cited violations ran from unapproved drug distribution to misbranding and manufacturing deficiencies. For a sector used to operating quietly, the sheer pace and volume was new, and every letter carried an unspoken next step: injunctions, seizures, and criminal referrals for anyone who ignored it.
The Amino Asylum warehouse raid. In June 2025, federal agents raided the warehouse operations of Amino Asylum, another well-known research peptide vendor. That raid changed the register of enforcement, moving it from paperwork to boots on the ground. It told every supplier watching that the FDA was prepared to use its heaviest tools, and it is widely treated as the moment several vendors started seriously reassessing how exposed they were.
Resolution of the semaglutide shortage. In February 2025, the FDA formally declared the semaglutide drug shortage over. That single administrative call closed the loophole that had let compounding pharmacies, and by extension some research peptide vendors, make and sell semaglutide analogs and GLP-1 compounds under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Once the shortage was resolved, keeping those compounds on the shelf got a lot riskier. Given how much revenue GLP-1-related compounds threw off, losing that category almost certainly weighed on the books.
The SAFE Drugs Act. Introduced in early 2026, the Strengthening and Advancing Federal Enforcement of Drugs Act would hand the FDA broader authority to go after entities distributing unapproved peptide products. It had not passed by the time Peptide Sciences closed, but its arrival was itself a signal: bipartisan Congressional appetite for tighter control of the peptide market was no longer hypothetical.
Quality failures and third-party testing. Independent testing outfits, Finnrick Analytics chief among them, published analyses that surfaced real quality problems across multiple vendors, Peptide Sciences included. The reports documented retatrutide counterfeits moving through the market and weak purity scores for CJC-1295 from several suppliers. Findings like these do more than embarrass a brand. They contradict the quality promises vendors sold to researchers and, because they are documented, they hand regulators evidence of potential misbranding.
Stack all of that up and you get what analysts have called an untenable operating environment. Faced with the choice between waiting for a letter, an inspection, or a raid, Peptide Sciences appears to have decided that closing on its own terms beat every alternative.
What does this mean for the research peptide market?
When Peptide Sciences closed, the market lost its single largest vendor overnight. Those roughly 990,000 monthly visits were not abstract traffic; they stood for a large population of researchers, academic institutions, and independent investigators who all woke up needing somewhere else to buy. The knock-on effects are still reshaping the space, and they cluster into a few clear patterns.
Immediate supply disruption. Anyone with an active project hit a wall. Researchers mid-way through longitudinal studies or multi-phase protocols had to either freeze the work or scramble to qualify a new source. Swapping vendors partway through a study is not neutral; it introduces fresh variables around compound purity, synthesis methodology, and batch consistency, any of which can quietly undermine data integrity. Institutions that ran standing orders or procurement agreements with Peptide Sciences had it worse still, because onboarding a replacement through an institutional purchasing system is its own multi-week bureaucracy even when nothing goes wrong.
Heightened quality concerns. You might expect a closure to lower the temperature on quality talk. It did the opposite. The same third-party testing that fed Peptide Sciences' risk calculus is now being pointed at everyone else. Researchers are asking sharper questions: is this purity number verified, what analytical method produced it, and does this certificate of analysis reflect genuine independent testing or a recycled template. The Finnrick Analytics findings on retatrutide counterfeits and substandard CJC-1295 batches taught the community to treat vendor claims as claims until proven.
Regulatory momentum. The pressure is not easing. RFK Jr. has publicly floated plans to reclassify peptides in a way that could rewrite how research compounds are categorized, sold, and regulated. Whether that becomes formal policy is still an open question, but the trajectory is not ambiguous: the low-oversight era for research peptide vendors is closing. Whoever is left faces more attention from the FDA, from state regulators, and from a customer base that now knows what to ask.
Market consolidation. With the biggest name gone, its demand did not evaporate; it redistributed. That is opportunity and hazard in the same breath. Vendors thin on quality systems, supply chain depth, or compliance discipline can buckle under the extra volume. Vendors built to document what they sell are positioned to earn the researchers who have stopped shopping on brand familiarity and started shopping on reliability and analytical proof.
The demand side is not going anywhere. Academic institutions, independent researchers, and scientific organizations still need high-purity research compounds. What has genuinely shifted is the bar: the standard of quality, transparency, and compliance that researchers now expect before they will trust a supplier at all.
What should researchers look for in a peptide supplier in 2026?
Choosing a supplier after Peptide Sciences is not the moment to relax standards; it is the moment to raise them. With quality failures now documented in the open, the due-diligence checklist below is not a wish list. It is the floor a research peptide vendor has to clear to be taken seriously in the current regulatory climate.
Batch-specific Certificate of Analysis. A real COA is documented for the batch. It is not something you have to email and ask for. It also has to be batch-specific, because a generic COA reused across production runs tells you nothing and should read as a red flag. Look for the concrete details: batch number, testing date, analyst, and the name of the lab that ran it. For a line-by-line walkthrough of what these documents should contain, see How to Read a Certificate of Analysis.
HPLC verification and mass spectrometry. High-Performance Liquid Chromatography is still the reference method for quantifying purity, and mass spectrometry is what confirms you actually have the molecule you paid for. A credible supplier runs both on every compound and can show you the chromatogram images, not just a tidy percentage typed onto a page. We go deeper on why these two methods matter, and how to read them, in our article on Peptide Purity.
Endotoxin testing. For compounds headed into cell culture, in vitro assays, and other sensitive laboratory work, bacterial endotoxin contamination is not a footnote; it can wreck an experiment. Limulus Amebocyte Lysate (LAL) testing or recombinant Factor C assays are how you catch it. A supplier that skips this step is economizing on one of the fundamentals.
Transparent purity data. Research-grade compounds should clear a 99%+ purity threshold. But the number alone is worth little. A serious supplier publishes its standard and backs each compound with its own analytical data rather than a blanket marketing line. Treat a purity figure that cannot be traced to underlying chromatographic evidence as decoration. Real transparency means putting the actual test data on the table, not just quoting a result.
US-based operations. Domestic operations buy you accountability, faster shipping, and a clearer regulatory jurisdiction to work within. Plenty of international suppliers make good compounds, but keeping things stateside simplifies disputes, returns, and quality complaints, and it puts the vendor under direct FDA oversight. That oversight is a constraint, sure, but for a researcher it also functions as a quality backstop.
None of these are aspirational extras. They are the baseline for sourcing research compounds responsibly at a moment when a quality failure can cost you more than a ruined experiment; it can put the researcher and the institution behind them in regulatory reach.
How is Ever Vital different?
Ever Vital was built for exactly the standard the research community is now insisting on. We are not trying to step into any one vendor's outline. We built our quality framework around the specific failures and blind spots the broader market has already put on display. Everything in the catalog is intended solely for research purposes.
The catalog is deliberately 64 research-grade compounds, each held to a minimum purity standard of 99%+ and confirmed by independent third-party analytical testing. Every batch has a corresponding Certificate of Analysis showing HPLC purity quantification and mass spectrometry identity confirmation. That paperwork is not an upsell or a request line; it is documented for every batch because that is simply how we operate.
Endotoxin testing runs on all compounds using validated detection methods. It is one of the first steps plenty of vendors quietly drop, or reserve for a handful of flagship products. For anyone running cell-based assays or otherwise sensitive protocols, that data is not a nicety. It is a prerequisite.
Ever Vital operates entirely within the United States, warehousing, customer service, and quality oversight all kept domestic. Researchers can browse our full catalog to see the available compounds, pricing, and how the categories are organized.
The premise is not complicated: independently verified, high-purity research compounds, complete analytical documentation, and careful handling at every link in the chain. In a market where trust took real damage from quality failures and vanishing vendors, our answer was never going to be a louder marketing voice. It is the documentation.
What products did Peptide Sciences carry?
Breadth was part of the Peptide Sciences pitch. The catalog ran to over 190 SKUs across a wide set of research categories: growth hormone secretagogues, metabolic research peptides, tissue repair and healing factors, cognitive and neuroprotective compounds, longevity and anti-aging research peptides, antimicrobial peptides, and cosmetic research compounds.
On the growth hormone secretagogue side you would find ipamorelin, CJC-1295 in both DAC and no-DAC variants, sermorelin, hexarelin, GHRP-2, and GHRP-6. The metabolic shelf leaned on GLP-1 receptor agonists, tirzepatide, semaglutide, and related compounds, the same category that drove much of the revenue until the semaglutide shortage resolution pulled the rug. Tissue repair was anchored by BPC-157, TB-500, and adjacent healing factors used heavily in musculoskeletal and wound repair research models. Longevity ran through epitalon, GHK-Cu, and NAD+ precursors, and the cognitive side covered several nootropic peptide families including selank and semax variants.
Ever Vital works across many of those same categories, but the guiding choice is depth over volume. Researchers coming from Peptide Sciences will recognize a good deal of overlap, including BPC-157, TB500, GHK-Cu, Ipamorelin, GLP-1, Sermorelin Acetate, CJC-1295 NO DAC, Epitalon, and NAD+. You can see everything at Browse all compounds.
We are not chasing the 190+ SKU count, and that is on purpose. Holding the catalog to 64 compounds is what lets us put real quality-control investment behind each one, independent third-party testing and endotoxin screening on every product, not just the ones that happen to sell well.
Is Peptide Sciences coming back?
Nothing suggests it is. The domain is still live, but all it serves is a static shutdown message, no reopening date, no contact for updates, nothing that reads as temporary.
Look at what would have to reverse for a return to make sense: ongoing FDA enforcement actions, proposed legislation widening the agency's authority, and the closed drug-shortage loopholes that once gave certain compound categories legal cover. None of that is trending toward reopening. The SAFE Drugs Act keeps moving through the legislative pipeline, and FDA enforcement has not eased off since the closure.
So the honest planning assumption is permanent, not paused. That means qualifying new suppliers now, proving out compound quality through independent testing, and lining up backup supply relationships so a single vendor is never again a single point of failure.
The lesson here is bigger than one company. A research supply chain that hangs on a single source carries risk no matter how established that source looks. A vendor pulling in $7.4 million per month vanished overnight with no warning; if that can happen, no relationship in this industry is too big to plan around.
The durable move is to spread your sources, keep verifying quality instead of assuming it, and stay current on where the regulation is heading. It also helps to keep your own copies, COAs, batch numbers, and analytical data from every order, held independently of any vendor's system, so your continuity does not depend on whether a supplier is still standing next quarter.
All compounds referenced in this article are research chemicals intended for laboratory and scientific research purposes only. Ever Vital does not sell products intended for human use. Researchers are responsible for ensuring compliance with all applicable local, state, and federal regulations governing the purchase and use of research materials.
